These top candidates were then used to create a classification model with high accuracy (AUC = 0.94), claiming that these autoantibodies could distinguish AD from other neurodegenerative diseases and showed better performance than Aβ and tau protein concentrations in CSF in predicting cognitive decline. The gene discussed is MAPT; the disease is Mental deterioration.